Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012 (2012), Article ID 940384, 5 pages
http://dx.doi.org/10.1155/2012/940384
Research Article

Peroxisome Proliferator-Activated Receptor Gamma Exacerbates Concanavalin A-Induced Liver Injury via Suppressing the Translocation of NF-κB into the Nucleus

1Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
2Department of Pharmacology, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita 565-0871, Japan

Received 19 July 2012; Revised 5 November 2012; Accepted 6 November 2012

Academic Editor: Yasuteru Kondo

Copyright © 2012 Yuji Ogawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Google Scholar · View at Scopus
  2. “A unified nomenclature system for the nuclear receptor superfamily,” Cell, vol. 97, no. 2, pp. 161–163, 1999.
  3. O. Bardot, T. C. Aldridge, N. Latruffe, and S. Green, “PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene,” Biochemical and Biophysical Research Communications, vol. 192, no. 1, pp. 37–45, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. K. L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J. A. Gustafsson, “Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440–1444, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. C. H. Lee, P. Olson, A. Hevener et al., “PPARδ regulates glucose metabolism and insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3444–3449, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. I. F. Charo, “Macrophage polarization and insulin resistance: PPARγ in control,” Cell Metabolism, vol. 6, no. 2, pp. 96–98, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Maeda, M. Takahashi, T. Funahashi et al., “PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein,” Diabetes, vol. 50, no. 9, pp. 2094–2099, 2001. View at Google Scholar · View at Scopus
  8. C. Hofmann, K. Lorenz, S. S. Braithwaite et al., “Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance,” Endocrinology, vol. 134, no. 1, pp. 264–270, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. R. B. Clark, “The role of PPARs in inflammation and immunity,” Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002. View at Google Scholar · View at Scopus
  10. F. Marra, E. Efsen, R. G. Romanelli et al., “Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells,” Gastroenterology, vol. 119, no. 2, pp. 466–478, 2000. View at Google Scholar · View at Scopus
  11. A. Galli, D. W. Crabb, E. Ceni et al., “Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro,” Gastroenterology, vol. 122, no. 7, pp. 1924–1940, 2002. View at Google Scholar · View at Scopus
  12. K. Matsusue, M. Haluzik, G. Lambert et al., “Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 737–747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Gavrilova, M. Haluzik, K. Matsusue et al., “Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass,” The Journal of Biological Chemistry, vol. 278, no. 36, pp. 34268–34276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Belfort, S. A. Harrison, K. Brown et al., “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2297–2307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPARγ2: Tissue-specific regulator of an adipocyte enhancer,” Genes and Development, vol. 8, no. 10, pp. 1224–1234, 1994. View at Google Scholar · View at Scopus
  16. G. Tiegs, J. Hentschel, and A. Wendel, “A T cell-dependent experimental liver injury in mice inducible by concanavalin A,” Journal of Clinical Investigation, vol. 90, no. 1, pp. 196–203, 1992. View at Google Scholar · View at Scopus
  17. W. Guo, W. Liu, S. Hong et al., “Mitochondrial-dependent apoptosis of con a-activated T lymphocytes induced by Asiatic Acid for preventing murine fulminant hepatitis,” PLoS One, vol. 7, no. 9, Article ID e46018, 2012. View at Google Scholar
  18. S. Maeda, L. Chang, Z. W. Li, J. L. Luo, H. Leffert, and M. Karin, “IKKβ is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFα,” Immunity, vol. 19, no. 5, pp. 725–737, 2003. View at Publisher · View at Google Scholar · View at Scopus